K. Alshammari

Efficacy and tolerability of cetuximab 750 mg/m2 every three weeks in metastatic colorectal cancer

BackgroundEarlier studies that established weekly dosing of cetuximab did not reach a maximum-tolerated dose. Subsequent pharmacokinetic studies showed equal efficacy and toxicity for the...

K. Alshammari ;

N. Alagel ;

H. Elhariry ;

M. Aseafan ;

B. Alshamsan ;

S. Bazarbashi ;

06/25/2023

Safety and efficacy of combined trans-arterial radioembolization and systemic therapy for advanced hepatocellular carcinoma

BackgroundThe current management of advanced hepatocellular carcinoma (HCC) is limited to systemic therapy alone. However the combination of trans-arterial radioembolization (TARE) and sy...

R. Madkhali ;

O. Bashir ;

K. Alshammari ;

A. Alolayan ;

M. Arabi ;

06/25/2023

Outcomes and prognostic factors of resected pancreatic ductal adenocarcinoma in Saudi Arabia

BackgroundPancreatic ductal adenocarcinoma, which comprises the majority of pancreatic cancers, is associated with poor survival. There are no local data describing the outcomes of resect...

M. Al-Hajeili ;

M. Alghamdi ;

A. Alfakeeh ;

A. Alzahrani ;

W. Alghareeb ;

A. Alnekhilan ;

A. Aljuhani ;

N. Bukhari ;

K. Alshammari ;

A. Qudaih ;

F. Alotaibi ;

M. Shaheen ;

H. Shehata ;

M. Alkaiyat ;

J. Al Qahtani ;

M. Algarni ;

A. Samman ;

F. Almugbel ;

A. Aldeheshi ;

06/25/2023

Clinical characteristics and outcomes of patients with hepatocellular carcinoma treated at a large multidisciplinary clinic in Saudi Arabia

BackgroundHepatocellular carcinoma (HCC) is the fourth most common solid tumor affecting adult males in Saudi Arabia and the condition poses a serious health threat to patients affected. ...

M. Algarni ;

R. Alanazi ;

K. Alshammari ;

A. Alammar ;

A. Alrashdi ;

H. Alrajih ;

N. Algazlan ;

J. Altwalah ;

F. Alotaibi ;

H. Shehata ;

M. Alkaiyat ;

J. Al Qahtani ;

A. Alolayan ;

M. Arabi ;

06/25/2023

Safety and efficacy of short cetuximab infusion for patients with metastatic colorectal cancer

BackgroundCetuximab is an FDA approved anti-EGFR monoclonal antibody that is given to patients with metastatic colorectal cancer (mCRC) who are KRAS and NRAS wildtype (wt). Dosing of cetu...

K. Alshammari ;

F. Alotaibi ;

H. Shehata ;

M. Alkaiyat ;

J. Al Qahtani ;

A. Alolayan ;

M. Algarni ;

Mohamed M. Ali ;

A. Abushara ;

A. Al-Abdulaali ;

06/25/2023